Drugs aim to shrink tumors, possibly spare patients surgery
NCT ID NCT06624475
Summary
This study is testing whether two different immunotherapy drug combinations can shrink high-risk basal cell skin cancers before surgery. About 30 patients will receive either a two-drug combo (Opdualag) or a single drug (Nivolumab) for a few months. The main goal is to see how well the drugs reduce or eliminate the cancer in the removed tissue, and in some cases, a strong response might allow a patient to skip surgery altogether.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Irvine
RECRUITINGIrvine, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.